Tolvaptan (jynarque) - medication for direct patient care (2)
Ended Awarded Last action
- Contract number
- 36C26222F0276
- Awardee
-
Otsuka America Pharmaceutical Inc. UEI QKABLBMA8FT9
- Awarding agency
-
Veterans Integrated Service Network 22
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $137,108
Award facts
- Contract value 46% obligated
- $297,067.94 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Rockville, MD 20850, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | -$22,851 | |
| Original award | $159,960 |
About this award
Otsuka America Pharmaceutical Inc. received a firm fixed-price delivery order valued at approximately $297K from the Department of Veterans Affairs Veterans Integrated Service Network 22 (VISN 22) for Tolvaptan (Jynarque), a specialty pharmaceutical medication used to treat autosomal dominant polycystic kidney disease and hyponatremia. The contract, awarded on April 8, 2022, with a completion date of September 30, 2022, was issued without a set-aside designation and is being performed in Potomac, Maryland. The delivery order supports direct patient care within the VA healthcare system for veterans requiring this specialized pharmaceutical treatment.
This contract is issued under Otsuka America Pharmaceutical Inc.'s existing Blanket Purchase Agreement with the VA's National Acquisition Center for Jynarque, valued at $83.3 million and expiring March 26, 2026. The BPA is structured under the Federal Supply Schedule for Pharmaceuticals and Drugs (FSS-61-IB), enabling multiple VA Integrated Service Networks to procure Jynarque efficiently. Otsuka America Pharmaceutical Inc. is a for-profit pharmaceutical manufacturer headquartered in Rockville, Maryland, and serves as a primary supplier of specialty pharmaceuticals to the VA, with a broader $396 million Federal Supply Schedule contract for pharmaceuticals and hematology products.
Quick answers
Who was awarded contract 36C26222F0276?
36C26222F0276 was awarded to Otsuka America Pharmaceutical Inc. by Veterans Integrated Service Network 22 (Veterans Health Administration) on April 8, 2022.
How much is contract 36C26222F0276 worth?
The government has obligated $137,108 on 36C26222F0276. Its current value, with exercised options, is $297,068.
Is contract 36C26222F0276 an order under another contract?
Yes. 36C26222F0276 is a delivery order under 36F79720D0099, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C26222F0276 competed?
The extent of competition for 36C26222F0276 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award